NCT05534789View on ClinicalTrials.gov

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

TerminatedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
Carcinoma, Renal Cell
Trial Locations (1)

10017

Pfizer New York, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY